Get the Stockscreener App
205.38
0.23%
0.23
Natera Inc stock is traded at $205.38, with a volume of 533.74K.
It is up +0.23% in the last 24 hours and down -13.20% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$205.61
Open:
$204.53
24h Volume:
533.74K
Relative Volume:
0.40
Market Cap:
$28.69B
Revenue:
$2.12B
Net Income/Loss:
$-309.19M
P/E Ratio:
-89.92
EPS:
-2.2841
Net Cash Flow:
$93.57M
1W Performance:
-10.97%
1M Performance:
-13.20%
6M Performance:
+47.08%
1Y Performance:
+16.43%
1-Day Range:
$203.62
$209.76
1-Week Range:
$203.62
$236.58
52-Week Range:
$125.38
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
205.76 | 28.67B | 2.12B | -309.19M | 93.57M | -2.2841 |
|
TMO
Thermo Fisher Scientific Inc
|
555.10 | 212.36B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
218.19 | 155.19B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
647.65 | 51.34B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
131.91 | 37.70B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
191.49 | 34.49B | 15.90B | 1.28B | 2.21B | 7.2842 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera director Sheena Jonathan sells $100k in stock By Investing.com - Investing.com Nigeria
Natera CEO sells $20.7 million in NTRA stock By Investing.com - Investing.com India
Natera sec. and chief legal officer sells $307k in stock - Investing.com
Natera CEO sells $20.7 million in NTRA stock - Investing.com
Natera Inc. president Fesko sells $830k in stock By Investing.com - Investing.com India
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock By Investing.com - Investing.com UK
Natera Inc: President Moshkevich sells $1.07 million in NTRA stock - Investing.com
Natera director Sheena Jonathan sells $100k in stock - Investing.com
Oversold Conditions For Natera (NTRA) - Nasdaq
Natera Inc (NTRA) Stock Price Down 7.82% on Feb 4 - GuruFocus
Principal Financial Group Inc. Has $69.11 Million Stake in Natera, Inc. $NTRA - MarketBeat
National Pension Service Invests $1.49 Million in Natera, Inc. $NTRA - MarketBeat
Trading Systems Reacting to (NTRA) Volatility - Stock Traders Daily
Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test - The Globe and Mail
Exploring US High Growth Tech Stocks This February 2026 - simplywall.st
Natera submits FDA approval for bladder cancer test By Investing.com - Investing.com Nigeria
Natera Files FDA PMA for Signatera CDx in Muscle-Invasive Bladder Cancer - Oncodaily
Natera, Inc. (NTRA) Stock Analysis: Potential Growth Amidst Strong Analyst Confidence - DirectorsTalk Interviews
FDA premarket approval sought for Signatera CDx test in MIBC - Urology Times
Natera Submits Signatera™ CDx PMA to FDA - MEXC
Natera Submits Premarket Approval Application for Molecular Residual Disease Test Signatera CDx - marketscreener.com
NTRA Submits PMA to FDA for Bladder Cancer Detection Innovation - GuruFocus
Natera submits Signatera(TM) CDx PMA to FDA - marketscreener.com
Natera submits FDA approval for bladder cancer test - Investing.com
Natera, Inc. (NASDAQ:NTRA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Inflation Data: Is now the right time to enter Natera IncQuarterly Portfolio Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
Natera, Inc. $NTRA Shares Purchased by New York State Common Retirement Fund - MarketBeat
Short Interest in Natera, Inc. (NASDAQ:NTRA) Declines By 27.2% - MarketBeat
A Look At The Fair Value Of Natera, Inc. (NASDAQ:NTRA) - Yahoo Finance
Natera, Inc. $NTRA Shares Purchased by Mirae Asset Global Investments Co. Ltd. - MarketBeat
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 2,413 Shares of Stock - MarketBeat
Michael Burkes Brophy Sells 1,867 Shares of Natera (NASDAQ:NTRA) Stock - MarketBeat
Natera (NASDAQ:NTRA) CFO Sells $188,575.52 in Stock - MarketBeat
Natera (NASDAQ:NTRA) CEO Sells $866,983.68 in Stock - MarketBeat
Natera CFO Brophy sells $1.19 million in shares By Investing.com - Investing.com South Africa
Natera CEO sells $1.4m in NTRA stock By Investing.com - Investing.com Nigeria
Natera CEO sells $1.4m in NTRA stock - Investing.com
Natera (NASDAQ:NTRA) Insider Sells $285,192.00 in Stock - MarketBeat
Natera (NASDAQ:NTRA) Insider John Fesko Sells 928 Shares - MarketBeat
Insider Selling: Natera (NASDAQ:NTRA) Insider Sells 784 Shares of Stock - MarketBeat
Natera co-founder Sheena Jonathan sells $115k in stock By Investing.com - Investing.com South Africa
Natera president sells $528k in NTRA stock By Investing.com - Investing.com South Africa
Natera president sells $528k in NTRA stock - Investing.com
Natera co-founder Sheena Jonathan sells $115k in stock - Investing.com
Natera SEC. Daniel Rabinowitz sells $450k in stock By Investing.com - Investing.com UK
Natera SEC. Daniel Rabinowitz sells $450k in stock - Investing.com
Natera: President Fesko sells $409k in stock By Investing.com - Investing.com South Africa
Natera: President Fesko sells $409k in stock - Investing.com
Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue - Insider Monkey
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation - BioSpace
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Feb 03 '26 |
Sale |
230.77 |
1,639 |
378,229 |
137,847 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Feb 02 '26 |
Sale |
230.72 |
85,299 |
19,680,040 |
127,881 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Feb 03 '26 |
Sale |
230.77 |
4,725 |
1,090,379 |
123,156 |
| Brophy Michael Burkes | CHIEF FINANCIAL OFFICER |
Feb 03 '26 |
Sale |
227.83 |
6,939 |
1,580,926 |
52,120 |
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
Feb 03 '26 |
Sale |
231.02 |
3,594 |
830,279 |
178,081 |
| Sheena Jonathan | CO-FOUNDER |
Feb 03 '26 |
Sale |
230.77 |
435 |
100,384 |
263,161 |
| RABINOWITZ DANIEL | SEC. AND CHIEF LEGAL OFFICER |
Feb 03 '26 |
Sale |
230.77 |
1,334 |
307,845 |
223,813 |
0.05%
5.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):